Search
for
Sort by
Research 31–60 of 1000+
- Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies
- 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
- Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
- Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study
- Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study
- Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen: A Phase III Research Study of Female Sexual Dysfunction in Women on Testosterone Patch Without Estrogen (APHRODITE)
- Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
- Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
- Efficacy of Placental-Derived Mesenchymal Stem Cell Exosome Therapy in Treating Androgenetic Alopecia: A Clinical Trial Study
- 42173 Racial and ethnic disparities in androgenetic alopecia clinical trials in the USA
- Progress of Phage Therapy for Acne Vulgaris
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
- The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
- Racial and Ethnic Disparities in Androgenetic Alopecia Clinical Trials in the United States
- A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia
- First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
- Teriflunomide in multiple sclerosis: an update
- Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases
- Review of Baricitinib in the Treatment of Alopecia Areata.
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Recent updates on Wnt signaling modulators: a patent review (2014-2020)
- A Botanical Compound for the Treatment of Alopecia Areata and Chemotherapy-Induced Alopecia
- Abstract SS02-02: Chemoprevention: Poised for Success
- America - A Diversity of Life Styles.
- New agents for cancer chemoprevention
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Combination Therapies and the Theoretical Limits of Evidence-Based Medicine